News Report · Oncology

FDA Approves Olaparib for BRCA-Mutated mCRPC: 24% rPFS Improvement in PROpel Trial

June 09, 2026

Clinical Perspective

The approval of olaparib for BRCA-mutated mCRPC represents a significant advancement in targeted therapy, offering a new option for patients who have limited treatment choices due to their genetic profile.

Dr. Rahul Verma · Oncology

Olaparib (Lynparza) improved radiological progression-free survival (rPFS) by 24% compared to placebo in patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in the PROpel trial (HR 0.76; 95% CI 0.62-0.94) ^[1].

Clinical Context

Metastatic castration-resistant prostate cancer is a challenging stage of prostate cancer characterized by disease progression despite androgen deprivation therapy. Patients with BRCA mutations are at an increased risk for aggressive disease and poorer outcomes. Current treatment options include androgen receptor inhibitors and chemotherapy, but these therapies may not be effective for all patients, particularly those with specific genetic mutations. The approval of olaparib offers a new targeted therapy option for this population, aiming to improve outcomes in patients with BRCA-mutated mCRPC.

Key Findings

The PROpel trial showed olaparib significantly improved rPFS by 24% versus placebo with abiraterone (HR 0.76; 95% CI 0.62-0.94) in patients with BRCA mutations ^[1].
The trial enrolled 796 patients with mCRPC, randomized 1:1 to receive either olaparib with abiraterone or placebo with abiraterone ^[1].
Event rates: 45% for olaparib plus abiraterone versus 59% for placebo with abiraterone ^[1].
The primary endpoint was investigator-assessed rPFS per RECIST version 1.1 for soft tissue and Prostate Cancer Working Group criteria for bone lesions ^[1].
Secondary endpoint analysis showed a median OS of 30 months for olaparib plus abiraterone versus 24 months for placebo with abiraterone ^[1].
Olaparib is administered at a dose of 300 mg orally twice daily, while abiraterone is given at 1000 mg orally once daily with prednisone ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Anemia reported with olaparib — monitor during treatment ^[1].
Fatigue reported — exact frequency not available in public source summary ^[1].
Nausea reported in patients receiving olaparib ^[1].
Diarrhea reported — exact frequency not available in public source summary ^[1].
Lymphopenia reported with olaparib ^[1].
Complete adverse event profile available in the full prescribing information for olaparib (Lynparza) ^[1].

What This Means for Clinical Practice

Olaparib is indicated for adult patients with BRCA-mutated mCRPC, providing a targeted treatment option based on genetic testing. The data supports a 24% improvement in rPFS, highlighting the potential benefit for this specific patient population. How will this impact treatment decisions for patients without BRCA mutations?

Study Design

The PROpel trial (NCT03732820) was a phase III, randomized, double-blind study that enrolled 796 patients with mCRPC. The primary endpoint was investigator-assessed rPFS evaluated according to RECIST version 1.1 and Prostate Cancer Working Group criteria. The trial was funded by AstraZeneca, and key limitations included the exclusion of patients with prior systemic therapy for mCRPC, which may affect generalizability. Further data on long-term outcomes and quality of life are still pending.

FAQ

What is olaparib (Lynparza) approved for?

Olaparib (Lynparza) is approved for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, based on the PROpel trial showing a 24% improvement in rPFS compared to placebo with abiraterone.

How does olaparib work?

Olaparib is a PARP inhibitor that targets cancer cells with BRCA mutations, preventing DNA repair and leading to cell death in these tumor cells.

What is the recommended dose of olaparib?

The recommended dose of olaparib is 300 mg taken orally twice daily with or without food. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of olaparib?

Common side effects of olaparib include anemia, fatigue, nausea, diarrhea, decreased appetite, lymphopenia, dizziness, and abdominal pain.

How does olaparib compare to abiraterone?

In the PROpel trial, olaparib combined with abiraterone showed a 24% improvement in rPFS compared to the placebo with abiraterone, indicating a potential benefit in patients with BRCA mutations.

Who qualifies for olaparib treatment?

Patients eligible for olaparib treatment are those with deleterious or suspected deleterious BRCA mutations who have metastatic castration-resistant prostate cancer and have not received prior systemic therapy for mCRPC.

FDA Approves Olaparib for BRCA-Mutated mCRPC: 24% rPFS Improvement in PROpel Trial

FDA Approves Olaparib for BRCA-Mutated mCRPC: 24% rPFS Improvement in PROpel Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

FDA Approves Relacorilant for Platinum-Resistant Ovarian Cancer: 16 Months OS Improvement

Verified HCP Portal